Esophageal Adenocarcinoma — Trials

Esophageal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 70
Recruiting: 45
Ph III recruiting: 4
Growth YoY: —
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (27)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02962063	Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	active not recruiting	Phase 1 / Phase 2	64	Memorial Sloan Kettering Cancer CenterOTHER	1	Sep 9, 2026	clinicaltrials
NCT04391049	Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery	active not recruiting	Phase 1	16	NRG OncologyOTHER	1	Sep 4, 2026